FDA Approvals and Trial Results: Teva, Natera, Glaukos Stocks Surge Today

Key Highlights

• Four healthcare stocks moved today on separate news events, including an FDA approval, a device designation, and fresh clinical trial results.
• Natera's blood test for early cancer detection received Breakthrough Device designation from the FDA, a status meant to speed up its regulatory review.
• Teva jumped after the FDA approved its new once-monthly injectable treatment for schizophrenia, the first of its kind in subcutaneous form.
• Glaukos posted strong Phase 4 results combining its eye implant with cataract surgery, while Pharvaris published positive late-stage data in The Lancet.

Today brought a mix of good news across very different corners of healthcare. One company got a green light from the FDA. Another published results in one of medicine's most respected journals. A third earned a special designation meant to speed up its path to market. Together, these four stocks show how varied catalysts, not just one big theme, can move healthcare stocks on any given day.

Natera (NASDAQ:NTRA): Cancer Screening Test Gets FDA Fast-Track Status

Natera is a global leader in cell-free DNA testing, offering products used in oncology, women's health, and organ health. The company's multi-cancer early detection assay, a blood test designed to screen for several types of cancer at once, received Breakthrough Device designation from the FDA. This status does not mean the product is approved for sale, but it does mean the FDA will work more closely with Natera and speed up the review process. The agency looked at data across 12 cancer types before granting the designation. Natera shares traded near USD 400.44, up 2.47% on the day as analysts pointed to the long-term potential of catching cancer earlier.

Glaukos Corporation (NYSE:GKOS): Eye Implant Plus Surgery Beats Surgery Alone

Glaukos is an ophthalmic medical technology company focused on treatments for glaucoma, corneal disorders, and retinal disease. The company announced positive topline results from a Phase 4 trial testing its iDose TR implant alongside cataract surgery in patients with glaucoma or high eye pressure. The study showed a meaningfully larger drop in eye pressure when the implant was used together with surgery compared to surgery alone, with no new safety concerns reported through three months. Glaukos shares traded around USD 162.48, up a modest 0.73% as investors weighed the data against a volatile trading week for the stock.

Teva Pharmaceutical Industries (NYSE:TEVA): First Once-Monthly Shot of Its Kind Wins FDA Approval

Teva is a global pharmaceutical company known for its generics business alongside a growing innovative medicines portfolio. The company received FDA approval for WELTRUZA, a new once-monthly injectable form of olanzapine for adults with schizophrenia. What makes it different is that it is injected under the skin rather than into the muscle, and it does not require a loading dose or hours of monitoring afterward, which has been a common barrier with older long-acting treatments. Teva shares jumped sharply, up 6.34% and trading near USD 41.74, as investors welcomed a potential new growth driver for the company's neuroscience business.

Pharvaris N.V. (NASDAQ:PHVS): Rare Disease Drug Data Makes The Lancet

Pharvaris is a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated angioedema. The company had results from its Phase 3 RAPIDe-3 study published in The Lancet, one of the most cited medical journals in the world. The study tested deucrictibant, an oral pill for treating sudden attacks of hereditary angioedema, a rare condition that causes painful swelling episodes. The drug met its main goal and all secondary goals, with patients seeing faster symptom relief compared to placebo. A decision from the FDA is expected in early 2027. Pharvaris shares traded around USD 31.72, up 1.92% on the day.

The Bottom Line

Not every healthcare stock move needs a single big theme behind it. Today's four names show that regulatory approvals, device designations, and trial publications can all land in the same stretch of days and send different parts of the healthcare sector moving at once. From cancer screening to eye surgery to rare disease treatment, these stories are a reminder that healthcare investing often means tracking several small, separate stories rather than one big one.